By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) - Investment bank Jefferies has increased its full-year 2012 revenue estimate for Sequenom to $85 million from a previous $76 million on better-than-espected early adoption of the firm's T21 test.
Registering provides access to this and other free content.
Already have an account?Login Now.
The New York Times' George Johnson muses on cancer's roots in multicellularity.
The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.
Jun Wang, the chief executive of BGI, has stepped down.
In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.